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proton pump inhibitors (ppis) are used for the long-term treatment of gastroesophageal disorders and 
the non-prescription medicines for acid reflux. However, there is growing concerns about PPI misuse, 
overuse and abuse. This study aimed to develop an animal model to examine the effects of long-term 
use of ppi in vivo. Twenty one Wistar rats were given omeprazole orally or intravenously for 30 days, 
and caerulein as a positive control. After euthanization, the serum and stool were collected to perform 
MS-based quantitative analysis of metabolites. We carried out 16S-based profiling of fecal microbiota, 
assessed the expression of bile acid metabolism regulators and examined the immunopathological 
characteristics of bile ducts. After long-term PPI exposure, the fecal microbial profile was altered and 
showed similarity to those observed in high-fat diet studies. The concentrations of several metabolites 
were also changed in various specimens. Surprisingly, morphological changes were observed in the bile 
duct, including ductal epithelial proliferation, micropapillary growth of biliary epithelium, focal bile 
duct stricture formation and bile duct obstruction. these are characteristics of precancerous lesions of 
bile duct. fXR and RXRα expressions were significantly reduced, which were similar to that observed 
in cholangiocarcinoma in TCGA and Oncomine databases. We established a novel animal model to 
examine the effects of long-term use of omeprazole. The gut microbes and metabolic change are 
consequences of long-term PPI exposure. And the results showed the environment in vivo tends to a 
high-fat diet. More importantly, we observed biliary epithelial hyperplasia, which is an indicator of a 
high-fat diet.
Proton Pump Inhibitors (PPIs) are one of the most prescribed drugs in many countries. It inhibits the 
H + /K + ATPase enzyme system in the stomach to suppress acid production, resulting in higher gastric pH. 
Long-term PPI use is an effective treatment for gastroesophageal disorders and Helicobacter pylori infec-
tion, and are taken without prescription to relieve heartburn1. Despite their increased usage and popularity, 
over-the-counter (OTC) PPIs such as omeprazole, lansoprazole and pantoprazole are prone to overuse and mis-
use. There are growing concerns in the medical community about the inappropriate and overuse of PPIs2–4.
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Long-term PPI use have been associated with adverse consequences, including chronic kidney injury, acute 
kidney injury, acute interstitial nephritis, hypomagnesemia, Clostridium difficile infection, community-acquired 
pneumonia, bone fracture and increased risks of gastric and periampullary cancers development and death5–8. 
Many of these are retrospective and longitudinal observational studies, therefore bias may be introduced and 
results can be influenced by confounding variables. Furthermore, the mechanisms behind the reported adverse 
effects remain unclear9,10.
PPI users tend to have a less healthy gut microbiome than non-users, with significant increase of Enterococcus, 
Streptococcus, Staphylococcus and Escherichia coli11. PPIs have been shown to cause changes in bile salt composi-
tion in Barrett’s esophagus patient12. In view of these, we postulated that chronic PPI use can lead to the build-up 
of unhealthy gut microflora and disrupts normal gallbladder and biliary functions to induce biliary tract diseases. 
In this study, we investigated the effects of long-term omeprazole exposure on fecal microbiome and pathophys-
iology of Wistar rats and discussed the possibility of promoting physiological change.
Results
Animal model of Omeprazole long-term treatment. In this study, we used a rat model to assess the 
effects of long-term omeprazole exposure to living organisms. In previous reports, caerulein (an analogue of the 
human gastrointestinal hormone cholecystokinin) was used to stimulate smooth muscle contraction and release 
of biliary and pancreatic enzymes. At high concentrations, caerulein is reported to stimulate the inflammation, 
acinar loss, and fibrosis typically found in pancreatitis13,14. We therefore adopted caerulein treatment (70 μg/kg) 
as a positive control. Omeprazole was administered orally (40 mg/kg) for 30 days. Intravenous saline was used as 
a negative control (Fig. 1).
Omeprazole caused fecal bacterial changes in rats. Gut microbiome shows that long-term omepra-
zole used leads to an increase in alpha-diversity(Fig. 2a). Unweighted and weighted UniFrac PCoA analysis also 
showed omeprazole-treated rats displayed a different fecal microbiome profile compared to the untreated rats 
(Fig. 2b). Although there was no statistically significant difference in microbial composition at the phylum level 
(Fig. 3 and Table 1), there was a notable increase in the Firmicutes/Bacteroidetes ratio in the omeprazole-treated 
rats (Table 1). Also, significant changes at the family level including Bifidobacteriaceae, Lactobacillaceae, 
Peptostreptococcaceae, Burkholderiaceae, Rikenellaceae, Deferribacteraceae, Saccharimonadaceae and 
Desulfovibrionaceae, and at genus level including Bifidobacterium, Enterorhabdus, Lavtobacillus, Romboutsia, 
Fournierella, Erysipelotrichaceae_UCG_004, Parasutterella, Alistipes, Mucispirillum, Lachnospiraceae_UCG_001, 
Butyricicoccus, Intestinimonas, Ruminiclostridium, Ruminiclostridium_9, Candidatus_Saccharimonas and 
Desulfovibrionaceae were identified in omeprazole-treated rats (Fig. 3).
Omeprazole-induced metabolites changes in rat. In this study, we examined the composition of 
metabolites isolated from serum and stools of rats after 30 days of omeprazole treatment. Several metabolites in 
serum and stool showed significant changes in concentrations. In rat serum, α-tocopherol, L-phenylalanine and 
L-tyrosine were lower in the omeprazole-treated group. In stool, arachidonic acid and stearic acid concentra-
tion were significantly lower in the omeprazole-treated group, whereas rhamnose and sorbitol were significantly 
higher (Fig. 4). These metabolites achieved a statistical significance of P < 0.05, however they did not pass the 
FDR threshold of 5%.
Omeprazole-induced neoplastic transformation of bile duct tissue. In this study, the bile duct 
epithelium of rats treated with caerulein (Fig. 5a-2, -3 and -4) and omeprazole (Fig. 5a-5, -6, -7 and -8) showed 
marked ductal epithelial proliferation. The pseudostratification of bile duct epithelium as well as micro papillary 
growth patterns resembled those of adenocarcinoma15. Ductal proliferating cells also revealed mild to moderate 
cytological atypia and increased mitotic activity. Morphological changes in the omeprazole group were confirmed 
by IHC analysis using keratin 19 (CK-19), a known marker for gastroenteropancreatic and hepatobiliary tum-
ors16. The CK-19 staining results showed rats treated with omeprazole developed focal bile duct strictures and 
bile duct obstruction (Fig. 5b).
Additional IHC analysis was performed on FXR and RXRα, which are the master transcriptional regulators 
of bile acid metabolism and has a protective role in carcinogenesis. FXR and RXRα play important roles in the 
malignancy of several cancers, including CCA17. In our study, staining using anti-FXR and anti-RXRα antibodies 
revealed that both FXR and RXRα were down-regulated in the bile duct of rats treated with omeprazole compared 
to control (Fig. 5c). Decreased FXR and RXRα RNA expression was also found in human cholangiocarcinoma 
Figure 1. Animal model of long-term omeprazole treatment. Schedule of drug administration in Wistar rats in 
30 days. Rats were treated with caerulein (positive control) 5 times per week (total 20 doses), omeprazole was 
administered orally 3 times per week (total 12 doses). Saline (negative control) was administered as a negative 
control.
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(CHOL) dataset in the TCGA database (Fig. 5d). In relation to other hepatobiliary cancers listed in the Oncomine 
database, cholangiocarcinoma had the lowest FXR and RXRα RNA expression when compared to the combined 
hepatocellular carcinoma and cholangiocarcinoma and also the hepatocellular carcinoma cases in the Woo Liver 
dataset (Fig. 5e).
Figure 2. Fecal microbiome distribution in rats with long-term omeprazole treatment. The feces of rats 
treated with and without omeprazole for 30 days were prepared for fecal microbiome profiling by high-
throughput sequencing of the 16s rRNA gene with the Illumina MiSeq system. (a) Alpha-diversity of 
omeprazole treated samples and untreated controls. Statistical comparison between two groups was performed 
with exact Wilcoxon-Mann-Whitney test and significant differences were obtained for all four indices (at 
α = 0.05) (b) Principal coordinate analysis (PCoA) plot based on Unweighted or Weight UniFrac distance of 
omeprazole treated samples and untreated controls. Significant difference in beta-diversity was evaluated with 
permutational multivariate analysis of variance (vegan::adonis, 1000 permutations) and beta-dispersion was 
quantified with betadisper (vegan::betadisper, 1000 permutations). Both indices achieved adonis P < 0.05 and 
betadisper P > 0.05.
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Discussion
Since the emergence of PPI in the 1970’s, it has been widely used for the treatment of a variety of gastric acid-related 
diseases. In recent years, focus on the adverse side effects of PPIs has gained growing concerns. Common side 
effects from taking to PPIs include headache, diarrhea, constipation, abdominal pain, flatulence nausea and rash18. 
In relation to cancer, only PPI-associated hypergastrinemia has been directly linked to gastric cancer19.
Figure 3. Gut microbiota is changed in rats with long-term omeprazole treatment. Linear discriminant analysis 
(LDA) effect size (LEfSe) analysis of gut microbiota changes in rats with long-term omeprazole treatment. 
Significant biomarkers were defined as taxa with a LDA score (log10) ≥ 2. (b) Significant taxa were highlighted 
on the cladogram. P: Phylum; C: Class; O: Order; F: Family; G: Genus. Bacteria at (c) family level and (d) genus-
level with significant changes in abundance with omeprazole treatment (LDA ≥2).
Phylum
Control Omeprazole
U-testMeana SDb Mean SD
Actinobacteria 0.001 0.000 0.000 0.000 0.11
Bacteroidetes 0.551 0.095 0.467 0.118 0.17
Epsilonbacteraeota 0.008 0.022 0.012 0.028 0.27
Firmicutes 0.417 0.109 0.499 0.121 0.17
Proteobacteria 0.023 0.009 0.019 0.009 0.96
Firmicutes/Bacteroidetes Ratio 0.757 1.069
Table 1. Bacterial phyla identified from the fecal microbiome of rats treated with omeprazole and control. 
aAverage proportion of identified phylum. bStandard deviation.
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In our study, the 30-day regimen in the 6-month laboratory rat is equivalent to approximately 3 years of 
exposure in human years20. Ductal epithelial atypia and cribriform and micropapillary growth patterns were also 
observed in bile duct epithelium under long-term exposure to omeprazole in Wistar rats. The proliferating ductal 
Figure 4. Comparison of metabolites between omeprazole-treated and control Wistar rats. Rats were sacrificed 
at the end of the experiment (day 30) and serum and stool were collected. The serum and stool metabolites 
were analyzed by GC-TOFMS. (a) Heatmap showing the abundance of the identified metabolites (b) Statistical 
comparison between treated and control rats was performed with exact Wilcoxon-Mann-Whitney test at 
α = 0.05. Three and five metabolites were found to show significant differences in serum and stool samples 
respectively.
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cells showed mild to moderate cytological atypia, similar to bile ductal dysplasia in cholangiocarcinoma(CCA) 
patients21. These morphological abnormalities were also found in the positive control group taking caeru-
lean, while absent in negative control (saline). Interestingly, this biliary epithelial hyperplasia also observed on 
Control Omeprazole
Omeprazole
(a)
Control Omeprazole
Omeprazole Omeprazole Omeprazole
RXRAFXR
Control          Omeprazole Control    Omeprazole 
(c)
(d) (e)
(b)
(1) Control       (2)Caerulein (3)Caerulein (4) Caerulein
(5) Omeprazole     (6) Omeprazole   (7) Omeprazole  (8) Omeprazole  
Figure 5. Omeprazole induced lesions in the bile duct. The animals were sacrificed after 30 days. Bile ducts were 
removed and washed with iced phosphate buffer solutions. The tissues were embedded in paraffin wax (a) HE 
stain and (b) stained with anti-CK-19 antibody and examined. The bile ducts of rat treated with PPIs display 
morphological distortion and thickening of the bile duct epithelium. (c) Stained with anti-FXR and RXRα 
antibodies. (d) RNA expression levels of FXR and RXRα in cholangiocarcinoma and normal liver obtained 
from the TCGA database. (e) The Oncomine™ (Compendia Bioscience, Ann Arbor, MI) database (http://www.
oncomine.org/) was used to compare relative gene expression levels of FXR and RXRα in (1) cholangiocarcinoma, 
(2) combined cholangiocarcinoma and hepatocellular carcinoma, and (3) hepatocellular carcinoma.
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C57Bl/6 J mice with a high-fat diet22. This means that the phenomenon caused by omeprazole in rats is related to 
the high-fat diet.
Omeprazole exposure affects gut microbiota and influences the composition similar to that observed in 
high-fat-diet animal models. The Firmicutes/Bacteroidetes ratio, which is a marker of high-fat diet, were increased 
in the omeprazole-treated group (Table 1)23. The Bifidobacteriaceae, Lactobacillaceae and Peptostreptococcaceae 
decreased abundance, Intestinimonas, Desulfovibrionaceae, Deferribacteraceae, Lachnospiraceae and 
Candidatus_Saccharimonas showed increase in abundance in omeprazole-treated rats (Fig. 3), similar changes 
were also observed in high-fat diet model24–26. Interestingly, such gut microbiota composition was also similar to 
that observed in cancer. Bifidobacteriaceae, Lactobacillales and Erysipelotrichaceae were reported to be reduced 
in CRC patients, and Lachnospiraceace, Rikenellaceae, Alistipes and Desulfovibrionaceae were increased in CRC 
patients27–30.
Interestingly, our global metabolite profiling identified unique metabolic changes in rats exposed to omepra-
zole. Specifically, we found significant lower concentrations of α-tocopherol, L-phenylalanine and L-tyrosine 
in omeprazole-treated rat serum. α-tocopherol is a fat-soluble vitamin E with potent antioxidant activity and 
is involved lipid metabolism31, and L-phenylalanine and L-tyrosine are aromatic amino acids and have been 
shown to decrease in high-fat diet mouse model32. In stool, the 20-carbon chain unsaturated fatty acid arachi-
donic acid and 18-carbon chain saturated fatty acid stearic acid were decreased in omeprazole-treated rat, both 
fatty acids are involved in lipid metabolism and biosynthesis of unsaturated fatty acid. Rhamnose (a 6-carbon 
deoxy-sugar) and sorbitol (six-carbon sugar alcohol) were elevated in omeprazole-treated rat and are involved 
in fructose and mannose metabolism33,34. These changes have been linked to high-fat diet-induced metabolism. 
Recent researches have highlighted the increased risks of multiple cancers with high-fat diets, including CCA35–37. 
Further studies are warranted to clarify the exact mechanism by which omeprazole can induce precancerous 
lesions in the bile duct.
CCA is the second most frequent primary hepatic malignancy, originating from biliary epithelial cells. CCA 
is known to develop through a multi-step progression38. This process typically starts with epithelial hyperplasia 
leading to dysplasia and eventually adenocarcinoma. CCA patients often do not respond well to conventional 
chemotherapy and radiotherapy, surgical resection remains the only effective therapy for early stage tumors39. 
Therefore it remains urgent to identify the molecular mechanisms underlying the development and progression 
of CCA for preventive and therapeutic purposes. In 2016, Chien et al. reported a dose-dependent association 
between PPI use and risk of periampullary cancers, including CCA6. The precancerous lesions we observed in 
rats under chronic PPI exposure provide further evidence to highlight the risk of long-term overuse of PPI. 
Gut microbiota changes in CCA patients and the effect of PPIs induced gut microbiome change had been inde-
pendently studied but never concurrently. We believe our study is first of its kind to report the association between 
long-term PPI use, changes in fecal microbiota and neoplastic transformation of biliary tissues. Microbiome anal-
ysis revealed significant imbalances in the fecal flora of rats exposed to PPIs compared to control. These results 
suggest that the gastric and gut microbiota was affected by the change in gastric pH and the symbiotic relationship 
was disrupted. Microorganisms and the surrounding tissue microenvironment can cross-talk and influence each 
other to contribute to cancer. Future investigations on how alterations in gut microbiome impact the development 
of CCA will help the development of strategies for CCA treatment and prevention.
We performed IHC staining to compare the FXR and RXRα protein expression in rat bile duct exposed to 
omeprazole versus control. The decrease in FXR and RXRα expressions observed in this study was in accordance 
with human cholangiocarcinoma datasets from Oncomine and TCGA. Interestingly, loss of FXR protects dia-
betic mice against diet-induced or genetic obesity and accelerates liver carcinogenesis40. In our animal models, 
the body weights of PPI-treated rats also remained unchanged compared with controls (Supplementary Fig. 1). 
Hence, the onset of early biliary tract abnormalities is difficult to observe.
It is well established that the gut microbiota has profound effects on bile acid metabolism, host metabolism 
and human health41,42. Imbalances to microbiome environment and bile acids may play important role in tumori-
genesis of CCA41,42. Regulation of this delicate balance as well as FXR/RXRα might provide promising therapeutic 
approaches to treating CCA patients.
We have established a novel animal model to observe the effects of long-term omeprazole use in vivo and 
discuss the potential risks of cholangiopathy. Overall, our results provide evidence that PPIs may be a risk factor 
for CCA development. In our design, the duration of PPI exposure is equivalent to 3 human years. We wish to 
emphasize that PPI should be use following proper treatment and deprescribing guidelines, and our work high-
lights the need for increase awareness of physicians, patients and general public potential risks associating with 
PPI misuse and overuse.
Materials and Methods
Animal study. A total of 21 Wistar rats were purchased from NARLabs (National Applied Research 
Laboratories, Taiwan). All animals were maintained and handled in an accredited facility in accordance with 
IACUC (Institutional Animal Care and Use Committee) guidelines and the animal study protocol was approved 
by the Affidavit of Approval of Animal Use protocol, Taipei Medical University (License NO:LAC-2016-0352). 
A long-term (30 days) experiment was designed. At six weeks of age, rats were randomly assigned to one of 
four exposure groups: (1) oral omeprazole (40 mg/kg) (SIGMA-ALDRICH, St Louis, MO) (2) saline as negative 
control group; or (3) caerulein (20 μg/kg) as a positive control group. All animals were sacrificed on day 30 upon 
completion of their designated schedule. Rat bile ducts were harvested and washed with ice-cold phosphate buff-
ered solutions for IHC analysis. Tissues were also embedded in paraffin wax for histological and immunological 
assays.
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immunohistochemistry. IHC performed as previously described43,44. In brief, sections were cut onto 
adhesive-coated glass slides at 4-µm thickness, de-waxed, re-hydrated with PBS, and followed by incubation with 
anti-farnesoid X receptor (FXR) (GTX113867: GENETEX, Hsinchu City, Taiwan) and anti-retinoid X receptor-α 
(RXRα) (GTX113829: GENETEX) antibodies. Immune complexes were detected using the ChemMate DAKO 
EnVision kit (K5001; DAKO, Carpinteria, CA), and then the slides were counter-stained with hematoxylin. A 
negative control was simultaneously performed by incubating the corresponding tissue sections in a solution 
without the primary antibody.
16S rRNA gene sequencing and NGS analysis. The stool of rats were collected at day 30, and purified 
by QIAamp Fast DNA Stool Mini Kit (QIAGEN, Germany). The library preparation follows the protocol of 16S 
Ribosomal RNA Gene Amplicons for the Illumina MiSeq System. Sequence reads have been deposited in the 
European Nucleotide Archive (ENA) under accession number PRJEB28574.
The universal primers (341 F and 805 R) that were used to amplify the V3-V4 region of the bacterial 16S rRNA 
genes were first removed from the demultiplexed, paired reads using cutadapt (v 1.12; DOI:10.14806/ej.17.1.200). 
The filtered reads were processed in the R environment (v 3.3.3) using R package DADA2 (v 1.3.5)45 following 
the workflow described in Callahan et al.46 without performing rarefying procedure. Briefly, the forward and 
reversed reads were filtered and trimmed based on the read quality score and read length. Dereplication was 
then performed to merge identical reads, then reads were subjected to the denoise DADA2 algorithm which 
alternate between error-rate estimation and sample composition inference until they converge on a jointly con-
sistent solution. Finally, the paired reads were merged that required a minimal of 20 bp overlap and chimeras 
were subsequently removed. At this point, we obtained a list of V3-V4 sequence variants (SVs) found in our 
samples that were inferred by DADA2, as well as the frequency of each SV in each sample. Taxonomy assign-
ment was performed using the SILVA database (v128)47 as the reference with a minimum bootstrap confidence 
of 80. Multiple sequence alignment of the SVs was performed with DECIPHER (v2.2.0) and phylogenetic tree 
was constructed from the alignment using phangorn (v2.2.0)48. The count table, taxonomy assignment results 
and phylogenetic tree were consolidated into a phyloseq object, and community analyses were performed 
using phyloseq (v1.19.1)49. The alpha-diversity indices were calculated using the estimate_richness function 
from the phyloseq package. Statistical comparison between treatment and control was performed with exact 
Wilcoxon-Mann-Whitney test (at α = 0.05). UniFrac distances were calculated using the GUniFrac package 
(v1.1) to assess the community dissimilarity between groups50. Principal coordinate analysis (PCoA) ordination 
on UniFrac distances was performed and the adonis and betadisper functions from the vegan package (v2.4; 
https://CRAN.R-project.org/package = vegan) were used to conduct statistical analysis for the dissimilarity of 
composition among groups and the homogeneity of dispersion respectively. Microbiota enrichment analysis 
between groups was carried out by using the Linear Discriminant Analysis (LDA) Effect Size (LEfSe) method 
with alpha set at 0.05 (Kruskal-Wallis and Wilcoxon tests) and logarithmic LDA score of 2 or more51 and visual-
ized as cladogram by using GraPhlAn52
Global metabolite profiling by GC-TOFMS. For each animal, serum and stool were removed, divided 
into small portions, flash-frozen in liquid nitrogen, and stored at −80 °C until sample preparation and analy-
sis. Standards for approximately 1,000 mammalian metabolites were obtained from SIGMA-ALDRICH, SANTA 
CRUZ BIOTECH(Dallas, TX), or AVANTI POLAR LIPIDS(Alabaster, AL). The standards were prepared in 
appropriate solutions and analyzed on gas chromatography time-of-flight mass spectrometry (GC-TOFMS) 
to establish in-house metabolite database. Sample preparation and metabolite quantification were performed 
according to the methods described in53–56. The frozen tissue and stool samples (50 ~ 100 mg) were homogenized 
on ice in 500-μL of a mixture of chloroform, methanol and water (1:2:1, v/v/v). The samples were then centri-
fuged at 13,000 rpm for 10 min at 4 °C, and a 150-μL aliquot of the supernatant was transferred to a sampling vial. 
The deposit was rehomogenized with 500-μL of methanol followed by a second centrifugation. Another 150-μL 
aliquot of supernatant was added to the same vial for drying. The residue was reconstituted with 500-μL of ace-
tonitrile and water (1:1). The residue was then derivatized with 80-μL of methoxyamine (15 mg/mL in pyridine) 
was added to the vial and kept at 30 °C for 90 min, followed by 10-μL retention index compounds (mixture of 
C10-C40, 50 μg/mL) and 80-μL BSTFA (1% TMCS) at 70 °C for 120 min for derivatization to take place.
A 1-μL aliquot of the derivatized solution was injected into an Agilent 7890 N gas chromatograph in splitless 
mode coupled with a time-of-flight mass spectrometry (LECO Corp., St. Joseph, MI) used for untargeted metabo-
lomics profiling. Separation was achieved on a Rxi-5ms capillary column (Crossbond 5% diphenyl/95% dimethyl 
polysiloxane; Restek) using helium as the carrier gas at a constant flow rate of 1.0 mL/min. The GC oven temper-
ature began at 80 °C for the first 2 min, then raised at a rate of 10 °C/min to 140 °C, then at 4 °C/min to 180 °C, 
10 °C/min to 240 °C, and 25 °C/min to 290 °C, and maintained at 290 °C for 4.5 min. The temperature of injection, 
transfer interface, and ion source was set to 270, 270, and 220 °C, respectively. The mass spectra were obtained 
with electron impact ionization (70 eV) at full scan mode (m/z 30–600) and an acquisition rate of 25 spectra/s.
The acquired MS files were exported in NetCDF format by ChromaTOF software (v4.22, LECO Corp., St. 
Joseph, MI). CDF files were extracted using custom scripts in the MATLAB (v7.0, Mathworks, Natick, MA) for 
data pretreatment procedures such as baseline correction, de-noising, smoothing, alignment, time-window split-
ting, and multivariate curve resolution57. Internal standards and any known artificial peaks, such as peaks caused 
by noise, column bleed and BSTFA derivatization procedure, were removed from the data set. Variance stabilizing 
normalization was performed on the resulting output data. Metabolite annotation was performed by comparing 
with reference standards in our in-house library. Commercially available mass spectral databases such as NIST 
library 2010 and LECO/Fiehn Metabolomics Library was also used for additional compound annotation (with a 
similarity threshed of 70%). Metabolomics data transformation was performed with variance stabilizing normal-
ization. Unsupervised consensus hierarchical clustering was performed using ConsensusClusterPlus (v 1.38.0)58 
9Scientific RepoRtS |          (2020) 10:866  | https://doi.org/10.1038/s41598-020-57612-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
with 10,000 iterations and 80% sample resampling from 2 to 10 clusters. The clustering result was visualized as a 
heatmap representation generated using ComplexHeatmap(v1.12.0)59. Statistical comparison between treatment 
and control was performed with exact Wilcoxon-Mann-Whitney test (at α = 0.05).
Analysis of RNA expression profiles using public databases. We analyzed RNA expression profiles 
of CCA patients from the Oncomine database and The Cancer Genome Atlas (TCGA). Level 3 RNA data (unc.
edu_CHOL.IlluminaHiSeq_RNASeqV2 Level 3.1.0.0) were obtained from TCGA database. The expression pro-
file of each patient was median-centered, log2-transformed and loaded into MySQL database. RNA expression 
levels of tumor tissue and normal bile duct tissue from the same patient were extracted and analyzed. Gene 
expression profiles of the Woo Liver dataset from the Oncomine database (www.oncomine.org) were examined 
and compared to our data.
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